{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Bal Pharma Stock Falls to 52-Week Low of Rs.73.04 Amidst Prolonged Downtrend
Bal Pharma's shares touched a fresh 52-week low of Rs.73.04 today, marking a significant milestone in the stock's ongoing downward trajectory. This new low reflects continued pressures on the company’s financial performance and market valuation within the Pharmaceuticals & Biotechnology sector.
Bal Pharma Stock Falls to 52-Week Low of Rs.73.04 Amidst Prolonged Downtrend
Bal Pharma’s shares touched a fresh 52-week low of Rs.73.04 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock declined by 2.05% during the trading session, underperforming its sector peers and continuing a trend of subdued market performance over the past year.
Bal Pharma Stock Falls to 52-Week Low of Rs.73.61 Amidst Prolonged Downtrend
Bal Pharma's shares reached a fresh 52-week low of Rs.73.61 today, marking a continuation of the stock's downward trajectory over recent sessions. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial and operational metrics.
Bal Pharma Stock Falls to 52-Week Low of Rs.74 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.74, marking a significant decline as the stock continues its downward trajectory over the past eight trading sessions.
Bal Pharma Stock Falls to 52-Week Low of Rs.74 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.74, marking a significant decline as the stock continues its downward trajectory over the past eight trading sessions. This fresh low reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector and highlights the challenges faced by the company in recent periods.
Bal Pharma Stock Falls to 52-Week Low of Rs.74.2 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.74.2 today, marking a significant decline amid a sustained downward trajectory over the past week. The stock’s performance contrasts sharply with broader market trends, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Why is Bal Pharma falling/rising?
On 24-Nov, Bal Pharma Ltd’s stock price fell sharply to ₹74.60, marking a decline of 3.04% and hitting a fresh 52-week low. This drop continues a sustained downward trend that has seen the stock underperform both its sector and the broader market indices over multiple time frames.
Bal Pharma Stock Falls to 52-Week Low of Rs.75 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.75 today, marking a significant decline amid a sustained period of negative returns and underperformance relative to its sector and benchmark indices.
Bal Pharma Stock Falls to 52-Week Low of Rs.75 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.75, marking a significant decline amid a sustained period of negative returns. The stock has been on a downward trajectory for six consecutive trading sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Bal Pharma Stock Falls to 52-Week Low of Rs.75 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.75, marking a significant decline amid a sustained period of negative returns. The stock has been trading below all key moving averages and continues to underperform its sector and benchmark indices.
Bal Pharma Stock Falls to 52-Week Low of Rs.75 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.75, marking a significant decline amid a sustained period of negative returns. The stock’s recent performance contrasts sharply with broader market gains, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Bal Pharma Stock Falls to 52-Week Low of Rs.75 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.75 today, marking a significant decline amid a sustained period of negative returns. The stock has experienced a six-day consecutive fall, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Bal Pharma Stock Falls to 52-Week Low of Rs.75 Amidst Prolonged Downtrend
Bal Pharma’s shares touched a fresh 52-week low of Rs.75 today, marking a significant decline amid a sustained downward trend. The stock has been under pressure for six consecutive sessions, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.
Bal Pharma Stock Falls to 52-Week Low of Rs.75.96 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.75.96, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past five consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Bal Pharma Stock Falls to 52-Week Low of Rs.75.96 Amidst Prolonged Downtrend
Bal Pharma has reached a new 52-week low of Rs.75.96 today, marking a significant decline amid a sustained downward trend over the past week. The stock has recorded losses for five consecutive trading sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Is Bal Pharma overvalued or undervalued?
As of November 14, 2025, Bal Pharma is considered an attractive investment due to its undervalued financial metrics, including a PE Ratio of 18.76 and an EV to EBITDA of 10.07, especially when compared to more expensive peers like Sun Pharma and Divi's Lab.
Is Bal Pharma overvalued or undervalued?
As of November 14, 2025, Bal Pharma is considered an attractive investment due to its undervalued status, with a PE Ratio of 18.76, an EV to EBITDA of 10.07, and a low PEG Ratio of 0.00, especially when compared to more expensive peers like Sun Pharma and Divi's Lab.
Is Bal Pharma overvalued or undervalued?
As of November 14, 2025, Bal Pharma's valuation has shifted to attractive, with a PE ratio of 18.76, an EV to EBITDA of 10.07, and a dividend yield of 1.49%, indicating it is fairly valued compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -34.27%.
Bal Pharma Q2 FY26: Margin Pressures Mount as Profitability Stumbles
Bal Pharma Ltd., a member of the Micro Laboratories Group specialising in pharmaceutical formulations, reported a challenging quarter ended September 2025, with consolidated net profit declining 31.73% year-on-year to ₹0.71 crores from ₹1.04 crores in the corresponding quarter last year. Whilst the company managed to post sequential growth of 255.00% from the abysmal ₹0.20 crores in Q1 FY26, the underlying operational metrics paint a concerning picture of sustained margin compression and profitability challenges.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
